KRAS and cancer: In addition to Kras, Ccl2, and Il1b, a battery of other transcripts originated within the signature of KRAS-mutant cancers derived from the transcriptomes of our cell lines, providing synthetic lethality candidates for in vivo KRAS dependency for future research.